NUVA

NuVasive, Inc. [NUVA] Stock Forecast

Q: What is NuVasive, Inc. stock symbol ?

NuVasive, Inc. is a US stock, located in San diego of Ca and trading under the symbol NUVA

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

NUVA Stock Summary

Earnings have grown 5.53% per last year.

EPS has increased from the previous year and become positive (Yearly statements)

EPS has increased from the previous quarter and is now positive. (Quarter statements)

The Moving Average Convergence Divergence (MACD) for NUVA recently turned positive (within last 10 days).

Earnings are expected to fall -100% next year

Profit margins (0.02%) are lower than the previous year (0.03%)

NUVA has less than 1 year of cash runway

Debt-to-Equity ratio of 1.02 is considered moderate, deeper research suggested.

In the News

NUVA Financial details

Company Rating

Strong Buy

Market Cap

2.08B

Income

28.45M

Revenue

1.23B

Book val./share

16.87

Cash/share

1.55

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

07 Nov 2023

P/E

73.24

Forward P/E

PEG

-5.09

P/S

1.7

P/B

2.33

P/C

P/FCF

-626.27

Quick Ratio

0.6

Current Ratio

1.25

Debt / Equity

1.02

LT Debt / Equity

0.61

EPS (TTM)

0.54

EPS next Y

EPS next Q

EPS this Y

-162.9%

EPS next Y

EPS next 5Y

EPS last 5Y

26.58%

Revenue last 5Y

1.76%

Revenue Q/Q

3.27%

EPS Q/Q

-821.65%

SMA20

SMA50

SMA100

Inst Own

106.24%

Inst Trans

1.05%

ROA

ROE

ROC

0.05%

Gross Margin

72%

Oper. Margin

Profit Margin

Payout

Shs Outstand

Shs Float

Target Price

52W Range

35.17-49.53

52W High

52W Low

RSI

Rel Volume

21.62

Avg Volume

1.41M

Volume

Perf Week

Perf Month

Perf Quarter

Perf Half Y

Beta

1.06893

Volatility

0%, 0%

Prev Close

Price

Change

NUVA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	21.04	21.97	20.43	22.08	20.95
Net income per share	0.24	1.23	-0.72	-1.24	0.7
Operating cash flow per share	4.19	4.43	3.62	3.53	2.95
Free cash flow per share	2.09	1.97	1.48	1.35	0.52
Cash per share	2.3	4.04	20.03	4.8	4.36
Book value per share	15.94	17.22	17.87	15.41	15.15
Tangible book value per share	0.4	2.88	4.03	-1.57	0.78
Share holders equity per share	15.94	17.22	17.87	15.41	15.15
Interest debt per share	12.23	13.93	31.15	19.92	17.84
Market cap	2.59B	4.11B	2.9B	2.71B	2.37B
Enterprise value	3.08B	4.6B	3.57B	3.47B	3.12B
P/E ratio	207.93	63.03	-77.96	-42.25	58.54
Price to sales ratio	2.36	3.52	2.76	2.38	1.97
POCF ratio	11.84	17.47	15.58	14.86	13.99
PFCF ratio	23.68	39.19	37.95	38.83	79.67
P/B Ratio	3.11	4.49	3.15	3.4	2.72
PTB ratio	3.11	4.49	3.15	3.4	2.72
EV to sales	2.8	3.94	3.4	3.04	2.6
Enterprise value over EBITDA	13.71	18.21	20.32	19.17	14.74
EV to operating cash flow	14.05	19.55	19.21	19.04	18.47
EV to free cash flow	28.1	43.85	46.78	49.74	105.18
Earnings yield	0	0.02	-0.01	-0.02	0.02
Free cash flow yield	0.04	0.03	0.03	0.03	0.01
Debt to equity	0.72	0.77	1.67	1.27	1.16
Debt to assets	0.35	0.37	0.57	0.47	0.45
Net debt to EBITDA	2.16	1.94	3.84	4.2	3.58
Current ratio	3.44	3.69	1.87	3.99	1.21
Interest coverage	2.7	3.04	0.49	1.49	3.72
Income quality	17.56	3.61	-5	-2.84	4.19
Dividend Yield	0.04	0	0	0	0
Payout ratio	8.01	0	0	0	0
Sales general and administrative to revenue	0.52	0	0	0	0.53
Research and developement to revenue	0.06	0.06	0.08	0.08	0.08
Intangibles to total assets	0.48	0.4	0.26	0.41	0.37
Capex to operating cash flow	-0.5	-0.55	-0.59	-0.62	-0.82
Capex to revenue	-0.1	-0.11	-0.1	-0.1	-0.12
Capex to depreciation	-0.84	-0.96	-0.78	-0.75	-0.95
Stock based compensation to revenue	0.02	0.03	0.02	0.02	0.02
Graham number	9.25	21.8	17.05	20.76	15.5
ROIC	0.1	0.06	0.01	0.02	0.03
Return on tangible assets	0.01	0.06	-0.02	-0.05	0.03
Graham Net	-8.96	-8.29	-8.53	-15.36	-13.06
Working capital	438.75M	557.42M	725.82M	601.53M	149.16M
Tangible asset value	21.11M	153.05M	207.1M	-80.94M	44.94M
Net current asset value	-255.13M	-205.75M	-211.98M	-556.44M	-490.4M
Invested capital	0.72	0.77	1.67	1.27	1.16
Average receivables	197.76M	204.01M	209.3M	210.73M	231.89M
Average payables	90.48M	101.52M	103.78M	113.01M	117.97M
Average inventory	260.24M	292.83M	306.52M	308.23M	327.22M
Days sales outstanding	65.1	66.1	71.94	68.71	75.73
Days payables outstanding	124.2	113.53	125.29	130.94	130.52
Days of inventory on hand	320.52	365.07	341.16	357.71	367.27
Receivables turnover	5.61	5.52	5.07	5.31	4.82
Payables turnover	2.94	3.21	2.91	2.79	2.8
Inventory turnover	1.14	1	1.07	1.02	0.99
ROE	0.01	0.07	-0.04	-0.08	0.05
Capex per share	-2.09	-2.45	-2.13	-2.18	-2.43

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	5.97	5.67	4.87	5.89	6.01
Net income per share	-0.02	-0.04	0.38	-0.02	0.14
Operating cash flow per share	1.18	1.04	0.75	0.04	0.69
Free cash flow per share	0.5	0.3	0.23	-0.64	-0.01
Cash per share	4.37	4.59	3.99	3.5	1.55
Book value per share	15.89	15.98	13.84	16.72	16.87
Tangible book value per share	-0.22	0.38	0.72	1.16	1.59
Share holders equity per share	15.89	15.98	13.84	16.72	16.87
Interest debt per share	19.41	19.39	16.1	19.34	17.24
Market cap	2.56B	2.28B	2.59B	2.16B	2.2B
Enterprise value	3.34B	3.05B	3.35B	2.98B	3.03B
P/E ratio	-715.96	-288.45	26.88	-532.61	74.7
Price to sales ratio	8.24	7.73	8.47	7.01	6.92
POCF ratio	41.55	42.04	55.35	1.1K	60.26
PFCF ratio	98.24	143.64	178.97	-65.05	-4.45K
P/B Ratio	3.09	2.74	2.98	2.47	2.47
PTB ratio	3.09	2.74	2.98	2.47	2.47
EV to sales	10.75	10.32	10.95	9.69	9.52
Enterprise value over EBITDA	102.64	73.89	74.92	69.95	49.42
EV to operating cash flow	54.21	56.19	71.54	1.51K	82.86
EV to free cash flow	128.19	191.99	231.34	-89.9	-6.11K
Earnings yield	0	0	0.01	0	0
Free cash flow yield	0.01	0.01	0.01	-0.02	0
Debt to equity	1.22	1.21	1.16	1.15	1.02
Debt to assets	0.46	0.46	0.45	0.46	0.43
Net debt to EBITDA	23.98	18.61	16.96	19.34	13.48
Current ratio	1.17	1.21	1.21	1.19	1.25
Interest coverage	-0.91	1	7.63	2.1	5.96
Income quality	-68.93	-27.44	1.94	-1.94	4.96
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.08	0.08	0.08	0.08	0.09
Intangibles to total assets	0.39	0.37	0.37	0.38	0.39
Capex to operating cash flow	-0.58	-0.71	-0.69	-17.84	-1.01
Capex to revenue	-0.11	-0.13	-0.11	-0.11	-0.12
Capex to depreciation	-0.97	-1.04	-0.88	-1.05	-1.12
Stock based compensation to revenue	0.02	0.02	0.03	0.02	0.03
Graham number	2.48	3.7	10.93	2.7	7.27
ROIC	0	0	0.01	-0.03	0.01
Return on tangible assets	0	0	0.02	0	0.01
Graham Net	-14.98	-14.53	-11.93	-14.36	-13.97
Working capital	121.95M	145.83M	149.16M	131.56M	145.68M
Tangible asset value	-11.64M	19.73M	44.94M	60.65M	84.27M
Net current asset value	-524.31M	-499.57M	-490.4M	-487.12M	-468.75M
Invested capital	1.22	1.21	1.16	1.15	1.02
Average receivables	232.5M	234.58M	242.48M	249.7M	258.56M
Average payables	119.73M	121.54M	119.82M	121.31M	120.54M
Average inventory	328.06M	336.35M	339.8M	342.27M	348.38M
Days sales outstanding	67.71	71.8	73.48	73.13	75.65
Days payables outstanding	129.9	132.76	119.3	127.42	119.51
Days of inventory on hand	348.12	379.48	335.69	360.48	352.86
Receivables turnover	1.33	1.25	1.22	1.23	1.19
Payables turnover	0.69	0.68	0.75	0.71	0.75
Inventory turnover	0.26	0.24	0.27	0.25	0.26
ROE	0	0	0.03	0	0.01
Capex per share	-0.68	-0.74	-0.51	-0.67	-0.7

NUVA Frequently Asked Questions

What is NuVasive, Inc. stock symbol ?

NuVasive, Inc. is a US stock , located in San diego of Ca and trading under the symbol NUVA

What is NuVasive, Inc. stock quote today ?

NuVasive, Inc. stock price is $- today.

Is NuVasive, Inc. stock public?

Yes, NuVasive, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 1.41M
Market Capitalization 2.08B
Employee 3K
CEO Mr. J. Christopher Barry
Headquarters San Diego,CA,US
IPO Date 2004-05-13
Website https://www.nuvasive.com

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.